Cardiome CHF drug tanks in Phase II trials

Cardiome Pharma said Oxypurinol failed the efficacy test in a study of 405 congestive heart failure patients. The 24-week study yielded no statistically significant benefits over placebo, didn't increase the time between hospitalizations, and didn't improve quality of life. CEO Bob Rieder said he was disappointed in the "unequivocal negative outcome" but will review the data before deciding the fate of the program.

- read this report from for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.